The recent large prospective TailorX trial has confirmed that chemotherapy should be spared for HR positive, HER2 negative early stage breast cancer patients over 50 years old and a RS ≤ 25 or those 50 years or less and a RS ≤ 15 [14]. The gene discussed is ERBB2; the disease is breast carcinoma.